Reported about 1 month ago
The recent FDA decision to remove a key weight-loss drug from its shortage list has sparked a legal challenge and re-evaluation period, allowing compounders and telehealth providers to continue operating amid uncertain supply. Even with potential changes, many believe the demand for compounded GLP-1 drugs will persist, providing a lucrative opportunity for these businesses. While concerns about drug quality and regulatory pressures loom, companies like Sesame and Ro have adapted their strategies to keep supplying patients with compounded medications, asserting that the shortage isn't over yet.
Source: YAHOO